Cholinesterase inhibitors for Parkinson's disease dementia

Maidment, Ian; Fox, Chris; Boustani, Malaz · 2006 · OpenAlex-citations

DOI: 10.1002/14651858.cd004747.pub2

archive: archived pipeline: cataloged verified

Get this paper ↗ (DOI — opens at the source; we link to it, we don't host it)

Summary

This Cochrane review evaluates the efficacy, safety, and tolerability of cholinesterase inhibitors for treating Parkinson’s disease dementia (PDD). The research was motivated by the known loss of cholinergic innervation in PDD, which suggests a potential therapeutic role for these agents, despite concerns that they might worsen Parkinsonian motor symptoms. The objective was to assess clinical outcomes including cognition, activities of daily living, neuropsychiatric features, and safety profiles. The authors conducted a systematic search of major healthcare databases, trial registers, and scientific meeting abstracts up to April 2005, supplemented by contact with pharmaceutical companies. The review included only randomized, double-blind, placebo-controlled studies. Only one study met the inclusion criteria: a 24-week trial by Emre et al. (2004) involving 541 patients with mild to moderately severe PDD. Participants were randomized in a 2:1 ratio to receive rivastigmine (titrated to 3–12 mg/day) or placebo. Data were analyzed using intention-to-treat methods, with outcomes measured via standardized scales such as the Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and the Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL). Rivastigmine demonstrated statistically significant improvements in cognition and daily functioning compared to placebo. On the ADAS-Cog, rivastigmine yielded a 2.80-point improvement (Weighted Mean Difference [WMD] -2.80, 95% CI -4.26 to -1.34, P = 0.0002). Patients also showed a 2.50-point improvement on the ADCS-ADL (95% CI 0.43 to 4.57, P = 0.02). Clinically meaningful improvement occurred in 5.3% more patients in the rivastigmine group, while meaningful worsening was 10.1% more common in the placebo group. However, tolerability was a significant issue. Rivastigmine was associated with a higher rate of withdrawals due to adverse events (Odds Ratio [OR] 2.44, 95% CI 1.32 to 4.48, P = 0.004). Specific adverse events significantly more frequent in the rivastigmine group included nausea (OR 3.25), vomiting (OR 11.66), and tremor (OR 2.80). Conversely, mortality was significantly lower in the rivastigmine group (OR 0.27, 95% CI 0.08 to 0.95, P = 0.04). The authors conclude that rivastigmine provides moderate improvements in cognition and activities of daily living for PDD patients, offering clinically meaningful benefit to approximately 15% of cases. However, the high rate of adverse events, particularly gastrointestinal symptoms and tremor, limits patient acceptability and treatment adherence. The review highlights the need for further studies involving other cholinesterase inhibitors, pragmatic measures such as time to institutionalization, and robust health economic analyses. The authors also note limitations in the current evidence base, including reliance on last observation carried forward methods and the lack of data on patient and caregiver quality of life.

Provenance

The full processing record for this entry. Every stage of this paper's journey through the pipeline is logged — what ran, with which tool and model, how many attempts it took, and when it last completed.

Summary generated by qwen3.6-27b-prismaquant on 2026-06-26; verification: verified.

Topics

Ranked by relevance to this paper. Hover a topic for its definition.

• mci dementia driving